Data on the molecular makeup and drug sensitivity of hundreds of patient samples could accelerate progress against the aggressive blood cancer acute myeloid leukemia.
Data on the molecular makeup and drug sensitivity of hundreds of patient samples could accelerate progress against the aggressive blood cancer acute myeloid leukemia.